ZEROSTACK CORP

ZeroStack’s President sells shares amid FDA Fast‑Track approval for its PI3K/AKT/mTOR inhibitor ZST‑102, a promising Phase IIa drug for pancreatic cancer.

ZeroStack Corp’s insider option buys reveal executive confidence amid a 17% stock drop—insight into leadership strategy, market sentiment, and cannabis sector risks.

ZeroStack Corp’s insider sale of 4.9 M shares for 50 M 0G tokens reshapes debt, liquidity, and AI strategy—find out how this move could signal a turnaround or a cautionary shift for investors.